Acadia pharmaceuticals reports first quarter 2025 financial results and operating overview

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced its financial results for the first quarter ended march 31, 2025. “2025 is off to a strong start for acadia, achieving total revenue of $244.3 million in the first quarter,” said catherine owen adams, chief executive officer. “daybue has achieved meaningful patient growth for the first time since the second quarter of 2024, serving more patients this quarter than in any prior quarter, and nuplazid continues t.
ACAD Ratings Summary
ACAD Quant Ranking